HAE 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (HAE)	n/a
시장 하위 25% (US)	1.4%
시장 상위 25% (US)	4.3%
업계 평균 (Medical Equipment)	1.7%
애널리스트 예측 (HAE) (최대 3년)	2.5%

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 HAE 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 HAE 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 HAE 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: HAE 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

Haemonetics 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well

Insufficient new directors

What You Can Learn From Haemonetics Corporation's (NYSE:HAE) P/E

First quarter 2025 earnings: EPS exceeds analyst expectations

President of Global Hospital notifies of intention to sell stock

Are Investors Undervaluing Haemonetics Corporation (NYSE:HAE) By 46%?

Haemonetics Corporation to Report Q1, 2025 Results on Aug 08, 2024

Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth

Haemonetics Corporation Launches Limited Market Release of its New VASCADE MVP XL Mid-Bore Venous Closure Device

CEO, President & Director exercised options and sold US$3.3m worth of stock

Haemonetics Corporation, Annual General Meeting, Jul 25, 2024

Executive VP notifies of intention to sell stock

New minor risk - Earnings quality

New minor risk - Earnings quality

Haemonetics Corporation Provides Revenue Guidance for the Fiscal Year 2025

Full year 2024 earnings released: EPS: US$2.32 (vs US$2.27 in FY 2023)

Does Haemonetics (NYSE:HAE) Deserve A Spot On Your Watchlist?

Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion

Haemonetics Corporation to Report Q4, 2024 Results on May 09, 2024

Haemonetics Corporation Receives FDA Clearance for New TEG®? 6s Global Hemostasis - HN Cartridge

Haemonetics Corporation (NYSE:HAE) completed the acquisition of Advanced Cooling Therapy, Inc.

Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate

Haemonetics Corporation: Improved Performance, Another Bolt-On Deal

Haemonetics Corporation (NYSE:HAE) has entered into a definitive agreement to acquire Advanced Cooling Therapy, Inc. for $160 million.

The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Haemonetics Corporation Updates Revenue Guidance for the Fiscal Year 2024

Haemonetics Corporation to Report Q3, 2024 Results on Feb 08, 2024

The Price Is Right For Haemonetics Corporation (NYSE:HAE)

Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS).

Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS).

Haemonetics: Solid Performance Of This Blood Play

Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today

Haemonetics Corporation Revises Revenue Guidance for the Fiscal Year 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Haemonetics (NYSE:HAE) A Risky Investment?

Haemonetics Offers Relatively Rare Momentum In A Tough Medical Device Environment

Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for CAD 345 million.

Haemonetics Corporation to Report Q2, 2024 Results on Nov 02, 2023

Independent Director notifies of intention to sell stock

Price target increased by 8.3% to US$109

Haemonetics' Fiscal Q1 2024: Blood, Sweat, And Stellar Gains

Haemonetics Corporation Elects Diane M. Bryant to Its Board of Directors

Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued

Insider notifies of intention to sell stock

Haemonetics Corporation to Report Q1, 2024 Results on Aug 08, 2023

Haemonetics Corporation to Report Q1, 2024 Results on Aug 08, 2023

Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

CEO, President & Director exercised options and sold US$6.6m worth of stock

Haemonetics Corporation Receives FDA Clearance for Enhancements to NexSys PCS(R) Plasma Collection System

Haemonetics Corporation, Annual General Meeting, Aug 04, 2023

Executive VP & CTO recently sold US$192k worth of stock

Consensus EPS estimates increase by 25%

Haemonetics Corporation Provides Revenue Guidance for the Fiscal Year 2024

Full year 2023 earnings released: EPS: US$2.27 (vs US$0.85 in FY 2022)

Insufficient new directors

Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?

Haemonetics Executing Well, But Valuation Dogged By Concerns About A Large Customer

Haemonetics Corporation Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Haemonetics: Earnings Rate Of Change Justifies High Multiples

Insider notifies of intention to sell stock

Investor sentiment improved over the past week

Haemonetics Corporation to Report Q3, 2023 Results on Feb 07, 2023

We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease

Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?

Price target increased to US$95.29

Price target increased to US$93.57

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Haemonetics Corporation Updates Revenue Guidance for the Year 2023

Haemonetics Q2 2023 Earnings Preview

Haemonetics Corporation Appoints Maryanne Farris as Principal Accounting Officer